EICHOR
● Completed
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis · Sponsor: Amylyx Pharmaceuticals Inc.
About this study
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (5)
| Forbes Norris MDA/ALS Research Center - California Pacific Medical Center | San Francisco, California, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| University of Massachusetts Memorial Medical Center | Worcester, Massachusetts, United States | — |
| University of Michigan Medical Center | Ann Arbor, Michigan, United States | — |
| Wake Forest Baptist Medical Center | Winston-Salem, North Carolina, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04516096